Fred Porter, Ph.D.

Senior Vice President, Technical Operations

Frederick W. Porter is senior vice president of technical development and manufacturing of BridgeBio’s gene therapy subsidiaries, including Aspa. Dr. Porter has held key scientific and management positions in academia and the biopharmaceutical industry including positions at Duke University, GlaxoSmithKline and Novartis Vaccines. Prior to joining BridgeBio, he served on the leadership team at the Duke Human Vaccine Institute where he oversaw the startup of its clinical product development and manufacturing program and commissioning of its manufacturing facility. As head of drug substance R&D at GSK, Dr. Porter led a global technical development team responsible for antigen manufacturing process development for the GSK vaccine portfolio. His R&D expertise includes production and characterization of vaccines, gene therapy vectors, nucleic acid and recombinant protein therapeutics. Dr. Porter received his Ph.D. in biochemistry from The University of Wisconsin-Madison, a M.S. in microbiology from Seton Hall University, and a B.S. in biochemistry from Rutgers University.